Rapid long-lasting biochemical and radiological response to sorafenib in a case of advanced hepatocellular carcinoma

Gerardi,Assunta   Maria Teresa; Stoppino,Luca  Pio; Liso,Arcangelo; Macarini,Luca; Landriscina,Matteo

doi:10.3892/ol.2013.1131

March 2013 Volume 5 Issue 3

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

March 2013 Volume 5 Issue 3

Full Size Image

Article

Rapid long-lasting biochemical and radiological response to sorafenib in a case of advanced hepatocellular carcinoma

Authors:
- Assunta Maria Teresa Gerardi
- Luca Pio Stoppino
- Arcangelo Liso
- Luca Macarini
- Matteo Landriscina
View Affiliations / Copyright

Affiliations: Unit of Clinical Oncology, Department of Medical and Surgical Sciences, University of Foggia, Foggia I-71100, Italy, Unit of Radiology, Department of Medical and Surgical Sciences, University of Foggia, Foggia I-71100, Italy, Unit of Hematology, Department of Medical and Surgical Sciences, University of Foggia, Foggia I-71100, Italy
Pages: 975-977
|
Published online on: January 11, 2013

https://doi.org/10.3892/ol.2013.1131
Expand metrics +

Abstract

The multikinase inhibitor sorafenib has demonstrated an overall survival benefit in phase III hepatocellular carcinoma (HCC) trials and has become the new standard of care for advanced stages of this disease. However, in clinical practice, the vast majority of patients obtain disease stabilization and occasionally tumor shrinkage. Furthermore, the appropriate timing of sorafenib therapy initiation, in order to maximize its clinical activity, remains under debate. We report a case of 4‑year sorafenib treatment in a patient with an advanced hepatitis C virus (HCV)‑related HCC with extensive infiltration of the inferior vena cava. Sorafenib treatment induced a rapid complete biochemical response and a long-term favorable outcome. Additionally, no major toxicities or detrimental effects on quality of life were observed. Thus, it is likely that a subgroup of human HCC may be highly sensitive to sorafenib; new molecular determinants are required to select those patients who may benefit from this therapy. Furthermore, a prompt initiation of treatment when the hepatic function is not compromised is a prerequisite for maximizing the clinical activity of sorafenib.

View Figures

View References

1	Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, et al SHARP Investigators Study Group: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 359:378–390. 2008. View Article : Google Scholar : PubMed/NCBI
2	Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, et al: Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 10:25–34. 2009. View Article : Google Scholar : PubMed/NCBI
3	Nakazawa T, Hidaka H, Shibuya A and Koizumi W: Rapid regression of advanced hepatocellular carcinoma associated with elevation of des-gamma-carboxy prothrombin after short-term treatment with sorafenib - a report of two cases. Case Rep Oncol. 3:298–303. 2010. View Article : Google Scholar
4	Di Lorenzo G, Imbimbo M, Leopardo D, Marciano R, Federico P, Buonerba C, Salvatore B, Marinelli A and Palmieri G: A long-lasting response to sorafenib treatment in an advanced hepatocellular carcinoma patient. Int J Immunopathol Pharmacol. 23:951–954. 2010.PubMed/NCBI
5	Chelis L, Ntinos N, Souftas V, Deftereos S, Xenidis N, Chamalidou E, Maltezos E and Kakolyris S: Complete response after sorafenib therapy for hepatocellular carcinoma in an HIV-HBV co-infected patient: Possible synergy with HAART? A case report Med Oncol. 28:S165–S168. 2010.PubMed/NCBI
6	Inuzuka T, Nishikawa H, Sekikawa A, Takeda H, Henmi S, Sakamoto A, Saito S, Kita R, Kimura T, Osaki Y and Kudo M: Complete response of advanced hepatocellular carcinoma with multiple lung metastases treated with sorafenib: a case report. Oncology. 81:152–157. 2011. View Article : Google Scholar : PubMed/NCBI
7	Sacco R, Bargellini I, Gianluigi G, Bertini M, Bozzi E, Altomare E, Battaglia V, Romano A, Bertoni M, Capria A, Bresci G, et al: Complete response for advanced liver cancer during sorafenib therapy: case report. BMC Gastroenterol. 11:42011. View Article : Google Scholar : PubMed/NCBI
8	Yau T, Yao TJ, Chan P, Wong H, Pang R, Fan ST and Poon RT: The significance of early α-fetoprotein level changes in predicting clinical and survival benefits in advanced hepatocellular carcinoma patients receiving sorafenib. Oncologist. 16:1270–1279. 2011.
9	Personeni N, Bozzarelli S, Pressiani T, Rimassa L, Tronconi MC, Sclafani F, Carnaghi C, Pedicini V, Giordano L and Santoro A: Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma. J Hepatol. 57:101–107. 2012. View Article : Google Scholar : PubMed/NCBI
10	Abbadessa G, Rimassa L, Pressiani T, Carrillo-Infante C, Cucchi E and Santoro A: Optimized management of advanced hepatocellular carcinoma: four long-lasting responses to sorafenib. World J Gastroenterol. 17:2450–2453. 2011. View Article : Google Scholar : PubMed/NCBI

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Rapid long-lasting biochemical and radiological response to sorafenib in a case of advanced hepatocellular carcinoma

This article is mentioned in:

Abstract

Figure 1

Related Articles